Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
-- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks --
-- Sequential enrollment planned for OPTIC third and fourth cohorts --
-- Company to host and webcast a discussion with key opinion leaders on
Adverum also announced enrollment plans for the third and fourth cohorts in the ongoing OPTIC trial. The third cohort (n=9) has been initiated and patients will be treated with ADVM-022 at a dose of 2 x 10^11 vg/eye, the same dose used in the second cohort. Subsequently, patients in the fourth cohort (n=9) will be treated with ADVM-022 at a dose of 6x10^11 vg/eye, the same dose used in the first cohort. Since inflammation has generally been mild and responsive to steroid eye drops, patients in the third and fourth cohorts will receive prophylactic steroid eye drops instead of prophylactic oral steroids.
- Zero rescue injection required for any patient based upon protocol-defined criteria:
- Loss of >10 letters in best corrected visual acuity (BCVA) (using the ETDRS protocol) from baseline AND intraretinal or subretinal fluid observed by spectral-domain optical coherence tomography (SD-OCT) – with an increase in fluid judged by the investigator to be the cause of the visual loss; or
- Increase in central subfield thickness >75 µm from baseline as assessed by SD-OCT; or
- Presence of vision-threatening hemorrhage due to macular degeneration.
- Retinal anatomy improvements as observed on OCT scans were sustained.
- Vision was maintained, demonstrated by stable mean BCVA compared to baseline.
- ADVM-022 was safe and well-tolerated, with no serious adverse events (SAEs), no dose limiting toxicities (DLTs), and no Grade 3 adverse events (AEs).
An additional analysis of 24-week safety data presented today showed that inflammation, which is anticipated with ocular gene therapy, was manageable with steroids.
OPTIC Phase 1 Clinical Trial Data from Cohort 1 (n=6)
|Dose of intravitreal injection ADVM-022||6 x 10^11 vg/eye|
|Mean age||79 years|
|Mean number of years since diagnosis||3.3 years|
|Mean number of prior anti-VEGF injections||35.3 injections (range 7-109)|
|Mean number of anti-VEGF injections in 8 months prior to screening||6.2 injections|
|Average annualized anti-VEGF injection frequency1||9.3 injections|
|Mean BCVA2 study eye
Approximate Snellen equivalent
|Mean CRT3 study eye||369.2 μm|
|Results following a single ADVM-022 dose:|
|Median follow-up (weeks)||34|
|Minimum/Maximum follow-up (weeks)||28-44|
|Follow-up cutoff date||October 1, 2019|
|Number of patients requiring anti-VEGF rescue injections||0 patients|
|Mean number of anti-VEGF rescue injections||0 injections|
|Change in BCVA:|
|Mean (ETDRS letters)||-1.5|
|Minimum/Maximum (ETDRS letters)||-9 / +5|
|Grade 3 adverse events (AEs) 4||0|
|Serious adverse events (SAEs)||0|
|Dose-limiting toxicities (DLTs)||0|
|1||Calculated based on number of anti-VEGF injections in past 8 months|
|2||Best corrected visual acuity (BCVA) as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) (i.e., sight charts)|
|3||Central retinal thickness (CRT), also referred to as central subfield thickness (CST) assessed using Optical Coherence Tomography (OCT) imaging and measured by independent Central Reading Center|
|4||Grade 3 or severe adverse event using CTCAE general guidelines criteria|
“The data for ADVM-022 are promising, as this is the first time that an intravitreal injection gene therapy has provided sustained efficacy for patients with wet AMD who currently require frequent ocular anti-VEGF injections to maintain their vision,” said Szilárd Kiss, M.D., retinal specialist, who presented the data at AAO. “Now, with a 34-week median follow up, a one-time treatment that achieves the goal of improving retinal anatomy and preserving vision would clearly be transformative for these patients and fulfill an important unmet need in wet AMD.”
Future Outlook – Planned Milestones
- Adverum plans to begin dosing patients in the third cohort of the OPTIC trial in the fourth quarter of 2019 and plans to begin enrollment in the fourth cohort in the first quarter of 2020.
- Adverum plans to present 52-week data from the first cohort of patients in the OPTIC trial as well as 24-week data from the second cohort of patients in the first half of 2020.
- Adverum plans to submit an investigational new drug application for the treatment of ADVM-022 in diabetic retinopathy in the first half of 2020.
- Adverum expects to be able to occupy its new corporate headquarters in
Redwood City, CA, by the end of this year, allowing for the expansion of in-house process development capabilities to the 1000-liter production scale.
|Podium Presentation Details:|
|Event:||2019 American Academy of Ophthalmology|
|Title:||24-week Results of Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)|
|Section:||Section VIII: Late Breaking Developments, Part I|
|Date:||October 11, 2019|
|Time:||4:26 p.m. – 4:31 p.m. PT|
|Location:||WEST 3002; Moscone Center, San Francisco, CA|
|Speaker:||Szilárd Kiss, M.D., Director of Clinical Research in the Department of Ophthalmology at Weill Cornell Medical College|
Key Opinion Leader Event and Webcast:
The Company will host an event with expert retinal specialists to discuss the OPTIC data presented at AAO. The discussion will be held on
About the OPTIC Phase 1 Trial of ADVM-022 in Wet AMD
The multi-center, open-label, phase 1 trial is designed to assess the safety and tolerability of a single intravitreal (IVT) administration of ADVM-022 in patients with wet AMD who are responsive to anti-vascular endothelial growth factor (VEGF) treatment. In the first cohort, patients (n=6) received ADVM-022 at a dose of 6 x 10^11 vg/eye and in the second cohort (n=6) 2 x 10^11 vg/eye. In the third cohort (n=9), patients will receive a dose of 2 x 10^11 vg/eye and in the fourth cohort (n=9), patients will receive a dose of 6x10^11 vg/eye. Patients in the first and second cohorts received prophylactic oral steroids, while patients in the third and fourth cohorts will receive prophylactic steroid eye drops. The primary endpoint of the trial is the safety and tolerability of ADVM-022 after a single IVT administration. Secondary endpoints include change in best-corrected visual acuity (BCVA), change in central retinal thickness (CRT) and macular volume, as well as mean number of anti-VEGF rescue injections and percentage of patients needing anti-VEGF rescue injections. Each patient enrolled in the study will be followed for a total of two years.
Eight leading retinal centers across the United States are participating in the OPTIC phase 1 trial for ADVM-022. For more information on the OPTIC phase 1 clinical trial of ADVM-022 in wet AMD, please visit https://clinicaltrials.gov/ct2/show/NCT03748784.
About ADVM-022 Gene Therapy
ADVM-022 utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 is administered as a one-time intravitreal injection, designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and to improve vision outcomes for wet AMD and diabetic retinopathy patients.
In recognition of the need for new treatment options for wet AMD, the
Adverum is currently evaluating ADVM-022 in the OPTIC study, a phase 1 clinical trial in patients 50 years and older with wet AMD. Additionally, Adverum plans to submit a New Drug Application for ADVM-022 for the treatment of diabetic retinopathy to the
About Wet Age-related Macular Degeneration (Wet AMD)
Age-related macular degeneration (AMD) is a progressive disease affecting the macula, the region of the retina at the back of the eye responsible for central vision. In patients with wet AMD, an aggressive form of AMD, abnormal blood vessels grow underneath and into the retina. These abnormal blood vessels leak fluid and blood into and beneath the retina, causing vision loss.
Wet AMD is a leading cause of vision loss in patients over 60 years of age, with a prevalence of approximately 1.2 million individuals in the U.S. and 3 million worldwide. The incidence of new cases of wet AMD in the U.S. is approximately 150,000 to 200,000 annually, and this number is expected to grow significantly as the country’s population ages.
The current standard-of-care therapy for wet AMD is anti-VEGF intravitreal injections. These are effective but typically require long-term eye injections every 4-8 weeks in order to maintain vision. Compliance with this regimen can be difficult for patients, caregivers, and healthcare systems, leading to undertreatment and resulting in loss of vision.
Statements contained in this press release regarding events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements regarding: Adverum’s plans for advancing ADVM-022, and the potential benefits of ADVM-022, all of which are based on certain assumptions made by Adverum on current conditions, expected future developments and other factors Adverum believes are appropriate in the circumstances. Adverum may not achieve any of these in a timely manner, or at all, or otherwise carry out the intentions or meet the expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks inherent to, without limitation: Adverum’s novel technology, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval; the results of early clinical trials not always being predictive of future results; the potential for future complications or side effects in connection with use of ADVM-022; obtaining regulatory approval for gene therapy product candidates; enrolling patients in clinical trials; reliance on third parties for conducting the OPTIC trial and vector production; and ability to fund operations through completion of the OPTIC trial and thereafter. Risks and uncertainties facing Adverum are described more fully in Adverum’s Form 10-Q filed with the
Investor and Media Inquiries: Investors:
Myesha Lacy Adverum BiotechnologiesVice President, Investor Relations and Corporate Communications email@example.com 1-650-304-3892 Corey Davis, Ph.D. Managing Director firstname.lastname@example.org 212-915-2577 Media: Cherilyn Cecchini, M.D. Account Supervisor email@example.com 646-876-5196
Source: Adverum Biotechnologies, Inc.